1580-Multi-modal Tumor Profiling in Ovarian Cancer

The paper describes the Swiss Tumor Profiler (TuPro) project, a prospective research initiative investigating the clinical utility of multi-omics molecular profiling for patients with high-grade serous ovarian cancer. By integrating data from DNA, RNA, proteins, and functional drug assays within a four-week window, researchers provided personalized treatment recommendations that altered standard care for 76% of participants. This comprehensive approach identified whole-genome amplification as a key predictor of poor survival and discovered that chemotherapy significantly increases cancer cell heterogeneity while reducing tumor burden. The study highlights how personalized maintenance therapies can extend overall survival by addressing the unique molecular signatures of individual tumors. Furthermore, the findings suggest that molecularly guided interventions should be considered earlier in the treatment process, specifically as adjuvant therapies prior to chemotherapy. Overall, the sources demonstrate a feasible workflow for precision oncology that captures the complex evolution of ovarian cancer across different disease stages.References:Jacob F, Wegmann R, Ficek-Pascual J, et al. A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy[J]. Nature Communications, 2026.前往小宇宙评论区与主播互动